Pierre Conan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Pierre Conan has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Cécile Voisset
Univ Brest, Inserm, EFS, UMR 1078, GGB, School of Medicine, 22 avenue Camille Desmoulins, Brest F-29200, France; Univ Brest, Inserm, IMT-A, UMR 1101, LaTIM, School of Medicine, 22 avenue Camille Desmoulins, Brest F-29200, France
3 shared publications - Gaëlle Friocourt
Reference Centre of Rare Disease With Intellectual Disability and Multiple Disabilities , CHRU de Brest , Brest , France
3 shared publications - Frédéric Bihel
Laboratoire d’Innovation Thérapeutique, UMR 7200 CNRS, Université de Strasbourg
2 shared publications - Lucile Gentile
Univ Brest, Inserm, EFS, UMR 1078, GGB, School of Medicine, 22 avenue Camille Desmoulins, Brest F-29200, France
2 shared publications - Adeel Nasir
Univ Brest, Inserm, EFS, UMR 1078, GGB, School of Medicine, 22 avenue Camille Desmoulins, Brest F-29200, France
1 shared publication - Alexis Boulinguiez
Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, Paris, France
1 shared publication
Latest Publications
- 8 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Identification d'inhibiteurs de la Cystathionine-β-Synthase, une enzyme dont la surexpression est impliquée dans la déficience intellectuelle dans la trisomie 21
La trisomie 21 est une maladie génétique causée par la présence d’un chromosome 21 supplémentaire. Les patients souffrent d’une dysmorphie crâniofaciale, une cardiomyopathie et un risque accru de développer la maladie d’Alzheimer. À cela s’ajoute une déficience intellectuelle, de gravité variable suivant les patients, pour laquelle il n’existe à ce jour aucun traitement pharmacologique. De nombreuses études se sont concentrées sur l’identification des gènes dont la triplication est impliquée dans la déficience intellectuelle afin de pouvoir développer un traitement pharmacologique. Ces études ont identifié deux gènes en particulier, localisés sur le chromosome 21 : DYRK1A, codant une tyrosine kinase régulant de nombreuses voies de signalisation, et CBS, codant la Cystathionine-Beta- Synthase, responsable de la métabolisation des acides aminés soufrés et de la production d’H2S, un gazotransmetteur important pour la transmission synaptique.Mon projet de thèse consiste à identifier des candidats-médicaments capables de diminuer l’activité enzymatique de CBS. J’ai ainsi identifié deux familles de molécules prometteuses qui ont en commun une grande affinité pour les ions métalliques. De plus, nous avons caractérisé le lien génétique entre l’activité de DYRK1A et CBS. Une meilleure compréhension de la relation existant entre ces deux enzymes devrait permettre d’identifier de nouvelles stratégies thérapeutiques pour traiter la déficience intellectuelle dans la trisomie 21.
- 8 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Identification d'inhibiteurs de la Cystathionine-β-Synthase, une enzyme dont la surexpression est impliquée dans la déficience intellectuelle dans la trisomie 21
La trisomie 21 est une maladie génétique causée par la présence d’un chromosome 21 supplémentaire. Les patients souffrent d’une dysmorphie crâniofaciale, une cardiomyopathie et un risque accru de développer la maladie d’Alzheimer. À cela s’ajoute une déficience intellectuelle, de gravité variable suivant les patients, pour laquelle il n’existe à ce jour aucun traitement pharmacologique. De nombreuses études se sont concentrées sur l’identification des gènes dont la triplication est impliquée dans la déficience intellectuelle afin de pouvoir développer un traitement pharmacologique. Ces études ont identifié deux gènes en particulier, localisés sur le chromosome 21 : DYRK1A, codant une tyrosine kinase régulant de nombreuses voies de signalisation, et CBS, codant la Cystathionine-Beta- Synthase, responsable de la métabolisation des acides aminés soufrés et de la production d’H2S, un gazotransmetteur important pour la transmission synaptique.Mon projet de thèse consiste à identifier des candidats-médicaments capables de diminuer l’activité enzymatique de CBS. J’ai ainsi identifié deux familles de molécules prometteuses qui ont en commun une grande affinité pour les ions métalliques. De plus, nous avons caractérisé le lien génétique entre l’activité de DYRK1A et CBS. Une meilleure compréhension de la relation existant entre ces deux enzymes devrait permettre d’identifier de nouvelles stratégies thérapeutiques pour traiter la déficience intellectuelle dans la trisomie 21.
- Open Access
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1) , 4732622
Cellular Functional Analyses of ARX Variants Reveal New Insights Into Genotype–Phenotype Correlations in Neurodevelopmental Disorders Among Male and Female Patients
Neurodevelopmental disorders (NDDs) encompass a wide range of conditions often linked to genetic causes, with mutations in the X‐linked ARX gene representing a recurrent contributor. ARX encodes a transcription factor critical for GABAergic neuron development and functioning, regulating the expression of key neurodevelopmental target genes. Variants in ARX result in a wide clinical spectrum, ranging from asymptomatic female carriers to severe developmental syndromes in both sexes. This study investigates the functional impact of 16 ARX variants, including known pathogenic, likely pathogenic, and novel de novo variants, some associated with atypical presentations such as sudden infant death. Using transient expression in N2a neuroblastoma cells, we employed a comprehensive functional approach—including luciferase reporter assays, Western blotting, immunofluorescence, and RT‐qPCR—to assess protein expression levels, subcellular localization, their interaction with known corepressors (TLE1 and CtBP1), and their transcriptional activity on selected ARX ‐known targets. Our results demonstrate that all tested variants disrupt normal ARX transcriptional function, with several also altering protein localization or expression. Remarkably, a subset of variants exhibited dominant‐negative effects, offering a compelling explanation for unexpectedly severe phenotypes in female patients, likely exacerbated by skewed X‐inactivation and other modifying factors. By integrating experimental data with a literature‐based review of published ARX variants, we provide refined genotype–phenotype correlations, highlighting the importance of mutation type, positional context within key ARX functional domains, and patient sex. Altogether, this study advances our understanding of the molecular mechanisms driving ARX ‐related NDDs, emphasizing the importance of functional testing for accurate variant interpretation and paving the way toward informed genetic counseling and potential therapeutic development.
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1) , 4732622
Open AccessCellular Functional Analyses of ARX Variants Reveal New Insights Into Genotype–Phenotype Correlations in Neurodevelopmental Disorders Among Male and Female Patients
Neurodevelopmental disorders (NDDs) encompass a wide range of conditions often linked to genetic causes, with mutations in the X‐linked ARX gene representing a recurrent contributor. ARX encodes a transcription factor critical for GABAergic neuron development and functioning, regulating the expression of key neurodevelopmental target genes. Variants in ARX result in a wide clinical spectrum, ranging from asymptomatic female carriers to severe developmental syndromes in both sexes. This study investigates the functional impact of 16 ARX variants, including known pathogenic, likely pathogenic, and novel de novo variants, some associated with atypical presentations such as sudden infant death. Using transient expression in N2a neuroblastoma cells, we employed a comprehensive functional approach—including luciferase reporter assays, Western blotting, immunofluorescence, and RT‐qPCR—to assess protein expression levels, subcellular localization, their interaction with known corepressors (TLE1 and CtBP1), and their transcriptional activity on selected ARX ‐known targets. Our results demonstrate that all tested variants disrupt normal ARX transcriptional function, with several also altering protein localization or expression. Remarkably, a subset of variants exhibited dominant‐negative effects, offering a compelling explanation for unexpectedly severe phenotypes in female patients, likely exacerbated by skewed X‐inactivation and other modifying factors. By integrating experimental data with a literature‐based review of published ARX variants, we provide refined genotype–phenotype correlations, highlighting the importance of mutation type, positional context within key ARX functional domains, and patient sex. Altogether, this study advances our understanding of the molecular mechanisms driving ARX ‐related NDDs, emphasizing the importance of functional testing for accurate variant interpretation and paving the way toward informed genetic counseling and potential therapeutic development.
- Open Access
- 21 November 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 193, 118758
Anti-prion drugs reduce endoplasmic reticulum stress and protect human dopaminergic neurons from death
- 21 November 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 193, 118758
Open AccessAnti-prion drugs reduce endoplasmic reticulum stress and protect human dopaminergic neurons from death
- Open Access
- 17 June 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (12) , 6769
Identification of 8-Hydroxyquinoline Derivatives That Decrease Cystathionine Beta Synthase (CBS) Activity
CBS encodes a pyridoxal 5′-phosphate-dependent enzyme that catalyses the condensation of homocysteine and serine to form cystathionine. Due to its implication in some cancers and in the cognitive pathophysiology of Down syndrome, the identification of pharmacological inhibitors of this enzyme is urgently required. However, thus far, attempts to identify such molecules have only led to the identification of compounds with low potency and limited selectivity. We consequently developed an original, yeast-based screening method that identified three FDA-approved drugs of the 8-hydroxyquinoline family: clioquinol, chloroxine and nitroxoline. These molecules reduce CBS enzymatic activity in different cellular models, proving that the molecular mechanisms involved in yeast phenotypic rescue are conserved in mammalian cells. A combination of genetic and chemical biology approaches also revealed the importance of copper and zinc intracellular levels in the regulation of CBS enzymatic activity—copper promoting CBS activity and zinc inhibiting its activity. Taken together, these results indicate that our effective screening approach identified three new potent CBS inhibitors and provides new findings for the regulation of CBS activity, which is crucial to develop new therapies for CBS-related human disorders.
- 17 June 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (12) , 6769
Open AccessIdentification of 8-Hydroxyquinoline Derivatives That Decrease Cystathionine Beta Synthase (CBS) Activity
CBS encodes a pyridoxal 5′-phosphate-dependent enzyme that catalyses the condensation of homocysteine and serine to form cystathionine. Due to its implication in some cancers and in the cognitive pathophysiology of Down syndrome, the identification of pharmacological inhibitors of this enzyme is urgently required. However, thus far, attempts to identify such molecules have only led to the identification of compounds with low potency and limited selectivity. We consequently developed an original, yeast-based screening method that identified three FDA-approved drugs of the 8-hydroxyquinoline family: clioquinol, chloroxine and nitroxoline. These molecules reduce CBS enzymatic activity in different cellular models, proving that the molecular mechanisms involved in yeast phenotypic rescue are conserved in mammalian cells. A combination of genetic and chemical biology approaches also revealed the importance of copper and zinc intracellular levels in the regulation of CBS enzymatic activity—copper promoting CBS activity and zinc inhibiting its activity. Taken together, these results indicate that our effective screening approach identified three new potent CBS inhibitors and provides new findings for the regulation of CBS activity, which is crucial to develop new therapies for CBS-related human disorders.